TY  - RPRT
TI  - Valuing Post-Revenue Biopharmaceutical Assets with Pfizer's Current Portfolio as a Case Study
AU  - Yongzhuo Chen
AU  - Yixuan Liang
AU  - Yiran Liu
AU  - Brian Hobbs
AU  - Michael Kane
PY  - 2023
UR  - https://arxiv.org/abs/2312.02250
ID  - 2312.02250
ER  -